Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life

V. Puente; O. De Fabregues; C. Oliveras; G. Ribera; C. Pont-Sunyer; R. Vivanco; G. Cucurella; E. Giralt; T. Delgado; C. Garcia; A. Seoane; R. Campo

doi:10.1016/j.parkreldis.2009.07.015

Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life

V. Puente, O. De Fabregues, C. Oliveras, G. Ribera, C. Pont-Sunyer, R. Vivanco, G. Cucurella, E. Giralt, T. Delgado, C. Garcia, A. Seoane, R. Campo

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

56 Cites (Scopus)

Resum

Symptom control, daily "on" time, and quality of life (QoL) of nine patients with Advanced Parkinson's Disease was assessed following 18-months treatment with Continuous Intraduodenal Levodopa Infusion (CIDLI). Patients had severe motor fluctuations and dyskinesias and had previously received treatment with oral levodopa and dopamine agonists. There were significant improvements in patients' symptoms on the Unified Parkinson's Disease Rating Scale, and QoL (Parkinson's Disease QoL Questionnaire; Schwab & England Capacity for Daily Living Scale; p < 0.05). Mean (±SD) daily "on" time increased from 6.1 ± 1.9 to 12.0 ± 3.4 h (p < 0.05). Improved QoL in APD was associated with CIDLI-related improvements in symptom control and increase in daily "on" time. © 2009.

Idioma original	Anglès
Pàgines (de-a)	218-221
Revista	Parkinsonism and Related Disorders
Volum	16
Número	3
DOIs	https://doi.org/10.1016/j.parkreldis.2009.07.015
Estat de la publicació	Publicada - 1 de març 2010

Accés al document

10.1016/j.parkreldis.2009.07.015

Com citar-ho

Puente, V., De Fabregues, O., Oliveras, C., Ribera, G., Pont-Sunyer, C., Vivanco, R., Cucurella, G., Giralt, E., Delgado, T., Garcia, C., Seoane, A., & Campo, R. (2010). Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life. Parkinsonism and Related Disorders, 16(3), 218-221. https://doi.org/10.1016/j.parkreldis.2009.07.015

@article{6d5cf466781d4847b36648b1fc1a6775,

title = "Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life",

abstract = "Symptom control, daily {"}on{"} time, and quality of life (QoL) of nine patients with Advanced Parkinson's Disease was assessed following 18-months treatment with Continuous Intraduodenal Levodopa Infusion (CIDLI). Patients had severe motor fluctuations and dyskinesias and had previously received treatment with oral levodopa and dopamine agonists. There were significant improvements in patients' symptoms on the Unified Parkinson's Disease Rating Scale, and QoL (Parkinson's Disease QoL Questionnaire; Schwab & England Capacity for Daily Living Scale; p < 0.05). Mean (±SD) daily {"}on{"} time increased from 6.1 ± 1.9 to 12.0 ± 3.4 h (p < 0.05). Improved QoL in APD was associated with CIDLI-related improvements in symptom control and increase in daily {"}on{"} time. {\textcopyright} 2009.",

keywords = "Continuous intraduodenal levodopa infusion, Duodopa, Fluctuations, Monotherapy, Parkinson's disease, Quality of life",

author = "V. Puente and {De Fabregues}, O. and C. Oliveras and G. Ribera and C. Pont-Sunyer and R. Vivanco and G. Cucurella and E. Giralt and T. Delgado and C. Garcia and A. Seoane and R. Campo",

year = "2010",

month = mar,

day = "1",

doi = "10.1016/j.parkreldis.2009.07.015",

language = "English",

volume = "16",

pages = "218--221",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier BV",

number = "3",

}

Puente, V, De Fabregues, O, Oliveras, C, Ribera, G, Pont-Sunyer, C, Vivanco, R, Cucurella, G, Giralt, E, Delgado, T, Garcia, C, Seoane, A & Campo, R 2010, 'Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life', Parkinsonism and Related Disorders, vol. 16, núm. 3, pàg. 218-221. https://doi.org/10.1016/j.parkreldis.2009.07.015

Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life. / Puente, V.; De Fabregues, O.; Oliveras, C. et al.
In: Parkinsonism and Related Disorders, Vol. 16, Núm. 3, 01.03.2010, pàg. 218-221.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life

AU - Puente, V.

AU - De Fabregues, O.

AU - Oliveras, C.

AU - Ribera, G.

AU - Pont-Sunyer, C.

AU - Vivanco, R.

AU - Cucurella, G.

AU - Giralt, E.

AU - Delgado, T.

AU - Garcia, C.

AU - Seoane, A.

AU - Campo, R.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Symptom control, daily "on" time, and quality of life (QoL) of nine patients with Advanced Parkinson's Disease was assessed following 18-months treatment with Continuous Intraduodenal Levodopa Infusion (CIDLI). Patients had severe motor fluctuations and dyskinesias and had previously received treatment with oral levodopa and dopamine agonists. There were significant improvements in patients' symptoms on the Unified Parkinson's Disease Rating Scale, and QoL (Parkinson's Disease QoL Questionnaire; Schwab & England Capacity for Daily Living Scale; p < 0.05). Mean (±SD) daily "on" time increased from 6.1 ± 1.9 to 12.0 ± 3.4 h (p < 0.05). Improved QoL in APD was associated with CIDLI-related improvements in symptom control and increase in daily "on" time. © 2009.

AB - Symptom control, daily "on" time, and quality of life (QoL) of nine patients with Advanced Parkinson's Disease was assessed following 18-months treatment with Continuous Intraduodenal Levodopa Infusion (CIDLI). Patients had severe motor fluctuations and dyskinesias and had previously received treatment with oral levodopa and dopamine agonists. There were significant improvements in patients' symptoms on the Unified Parkinson's Disease Rating Scale, and QoL (Parkinson's Disease QoL Questionnaire; Schwab & England Capacity for Daily Living Scale; p < 0.05). Mean (±SD) daily "on" time increased from 6.1 ± 1.9 to 12.0 ± 3.4 h (p < 0.05). Improved QoL in APD was associated with CIDLI-related improvements in symptom control and increase in daily "on" time. © 2009.

KW - Continuous intraduodenal levodopa infusion

KW - Duodopa

KW - Fluctuations

KW - Monotherapy

KW - Parkinson's disease

KW - Quality of life

U2 - 10.1016/j.parkreldis.2009.07.015

DO - 10.1016/j.parkreldis.2009.07.015

M3 - Article

SN - 1353-8020

VL - 16

SP - 218

EP - 221

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

IS - 3

ER -

Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life

Resum

Accés al document

Fingerprint

Com citar-ho